SLC5A2 and hydrops fetalis: While many studies on the effect of SGLT2 inhibitors on cardiovascular endpoints have been conducted, little is known about their effect on exercise capacity in HF patients, emphasizing the need to evaluate the potential effects of SGLT2 inhibitors on exercise tolerance in HF patients.